Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to verify superiority of the lafutidine group over the placebo
group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the
patients with mild reflux oesophagitis.
Furthermore, the followings are compared:
The improvement effect in heartburn and other subjective symptoms, and dosing frequency of
MALFA ® suspension (neutralizer) as well as incidence of adverse events among the lafutidine
20 mg/day treatment group, the famotidine 40 mg/day treatment group and the placebo treatment
group in patients with mild reflux oesophagitis.